Chrysalis Biotherapeutics begins contract with NIAID for TP-508 as nuclear countermeasure Feb. 9, 2017
Promising phase III topline results for CAM-2038 to treat moderate to severe opioid use disorder Nov. 14, 2016
Omeros reports results from phase II study of PPARgamma agonist in cocaine use disorder Oct. 20, 2016
RSS